| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | -0.22 | 0.1 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.044 | 0.1 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.077 | 0.1 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |